StreetAlpha.app
Home › Stocks › BMRN

Biomarin Pharmaceutical Inc (BMRN)

Healthcare
$60.41
▼ −1.64%
LAST CLOSE · NOV 20

BioMarin Pharmaceutical develops and sells medicines for people with rare genetic diseases. It last closed at $60.41 on Nov 20, down 1.64% on the day. The next earnings report for BMRN is expected around Tue, Jan 5, 2027, after the close. For the quarter ended Sep 2026, BMRN reported EPS of -$0.63 on revenue of $1.02B, with revenue up 32.0% from a year ago. Over its last 8 reports the stock moved an average of 2.3% the session after earnings. Over the last 12 months BMRN insiders bought $0 of stock on the open market and sold $4.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is BMRN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BMRN.

Key Stats

Last 12 months
Results
Revenue
$3.7B
+18.1% vs a year ago
Net income
−$19.1M
−103.7% vs a year ago
EPS (diluted)
−$0.10
−103.7% vs a year ago
Free cash flow
$557.9M
15.3% margin
Valuation
Market cap
$11.7B
193.7M shares
P/E
–
No P/E while losing money
Price to sales
3.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$736.0M
At Sep 30
Debt
$4.2B
At Sep 30
Shareholder equity
$6.3B
Shares outstanding
193.7M
At Oct 26
CEOJean Jacques Bienaime
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.8B$1.8BFY2021FY2022: $2.1B$2.1BFY2022FY2023: $2.4B$2.4BFY2023FY2024: $2.9B$2.9BFY2024FY2025: $3.2B$3.2BFY2025

From BMRN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Jan 5
Estimated date · After the close
Reported EPS
-$0.63
Quarter ended Sep 2026
Year ago EPS
-$0.16
Same quarter last year
Revenue
$1.02B
+32.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.65Dec '24Mar 2025: $0.95Mar '25Jun 2025: $1.23Jun '25Sep 2025: -$0.16Sep '25Dec 2025: -$0.24Dec '25Mar 2026: $0.54Mar '26Jun 2026: $0.23Jun '26Sep 2026: -$0.63Sep '26Latest -$0.63
Revenue by quarter
Dec 2024: $747.3MDec '24Mar 2025: $745.1MMar '25Jun 2025: $825.4MJun '25Sep 2025: $776.1MSep '25Dec 2025: $874.6MDec '25Mar 2026: $766.2MMar '26Jun 2026: $989.7MJun '26Sep 2026: $1.02BSep '26Latest $1.02B
How BMRN moved after its last 8 reports
Average move the session after a report ±2.3%
Oct 6, 2026After the close−1.8%
Aug 6, 2026After the close+3.8%
May 4, 2026After the close−4.0%
Feb 23, 2026After the close−0.5%
Jan 12, 2026After the close−4.3%
Oct 7, 2025After the close−0.0%
Aug 4, 2025After the close+2.7%
May 1, 2025After the close−1.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BMRNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BMRN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BMRN

Technical Analysis

BMRN · as of the Nov 20 close · updated each morning
Turning up

The stock is 5% above its 20 day and 3% above its 50 day average. It is 3% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 59). The nearest support is the Pivot S1 at $59.49, and the nearest resistance the swing high (Jul 17) at $60.64.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchNormal
VolatilityHigh, 3.3%/day
Key levels
$70.9852 week high+17.5%
$61.67Pivot R1+2.1%
$60.75Pivot+0.6%
$60.73100 day average+0.5%
$60.64Swing high (Jul 17)+0.4%
$60.41Last close
$59.49Pivot S1−1.5%
$58.92Swing low (Jul 31)−2.5%
$58.53200 day average−3.1%
$58.3250 day average−3.5%
$57.5920 day average−4.7%
$49.2652 week low−18.5%
Indicators
RSI (14)59.30Middle of its rangeNeutral
MACD0.68Above its signal lineBullish
Stochastic81.9Near the top of its rangeOverbought
ADX (14)19.3No clear trend
Williams %R-29.9Oversold below −80, overbought above −20Neutral
CCI (20)154.2Oversold below −100, overbought above 100Overbought
Rate of change+7.8%Change over 10 sessionsBullish
ATR (14)$1.99Typical daily range, 3.3% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Above
What happened before, for BMRN

What happened before

See how BMRN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BMRN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BMRN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BMRNHow many large options trades hit BMRN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

BMRN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●283 buying vs 256 selling
  • ▼Held by funds -6.5 pts
  • ●Funds holding +5
  • ●Superinvestors: 3 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding584579+0.9%
In funds' top 101714+21.4%
Held by funds100.1%106.5%−6.5 pts
New / increased82 / 20183 / 205−1.7%
Reduced / sold out184 / 72196 / 82−7.9%
Put/call ratio0.440.35+23.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BMRN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BMRN Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4.6M6 sales · 3 insiders
2026-02 sold $2.0M2026-03 sold $997K2026-05 sold $177K2026-09 sold $1.2M2026-11 sold $303KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Gregory R FribergEVP, Chief R&D OfficerSale5,147$58.81$303K
Sep 2George Eric DavisEVP, Chief Legal OfficerSale17,557$66.28$1.2M
May 7Gregory R FribergEVP, Chief R&D OfficerSale3,281$53.85$177K
Mar 11Charles Greg GuyerEVP, Chief Technical OfficerSale16,486$60.46$997K
Feb 26George Eric DavisEVP, Chief Legal OfficerSale26,061$61.36$1.6M
Feb 26Gregory R FribergEVP, Chief R&D OfficerSale6,326$60.38$382K
Every insider buy and sale for BMRN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BMRN insider trades →

From SEC Form 4 filings by BMRN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BMRN is in one of them and how their past BMRN trades turned out.

BMRN in the AI portfolios
Loading…

BMRN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BMRN in an article yet. Here's the latest on the wider market.

BMRN in the news

BMRN Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Apr 17
Who traded BMRN · since 2014
Latest 5 filings of 21
$1K – $15KTraded Mar 6, 2023Filed Apr 17, 2023
$1K – $15KTraded Oct 18, 2021Filed Nov 15, 2021
$15K – $50KTraded Dec 30, 2020Filed Jan 11, 2021
$1K – $15KTraded Oct 16, 2020Filed Nov 5, 2020
$1K – $15KTraded Sep 15, 2020Filed Oct 13, 2020
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KMar 6, 2023Apr 17, 202342 d
Josh GottheimerD · NJSell$1K – $15KOct 18, 2021Nov 15, 202128 d
Gilbert CisnerosD · CABuy$15K – $50KDec 30, 2020Jan 11, 202112 d
Josh GottheimerD · NJBuy$1K – $15KOct 16, 2020Nov 5, 202020 d
Josh GottheimerD · NJSell$1K – $15KSep 15, 2020Oct 13, 202028 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Biomarin Pharmaceutical

BioMarin Pharmaceutical develops and sells medicines for people with rare genetic diseases. Its products include VOXZOGO, a treatment for achondroplasia, the most common form of short stature caused by a genetic condition, and several enzyme therapies for conditions such as mucopolysaccharidosis and phenylketonuria. The company is based in California, and its customers are patients and the specialists who prescribe its treatments.

Headquarters
Novato, CA
Founded
1997